https://pioneerinstitute.org/wp-content/uploads/MBTA-Subway-Returns-Feature.jpg 450 600 Eamon McCarthy Earls https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Eamon McCarthy Earls2019-04-01 16:48:532019-07-11 11:23:44MBTAAnalysis: A look inside the MBTA
The MBTA shuttles over a million passengers a day around Greater…
https://pioneerinstitute.org/wp-content/uploads/CloseupClock-1.jpg 739 1244 Mary Connaughton https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Mary Connaughton2017-02-20 12:34:192017-02-21 09:47:58The Clock is Ticking…….
The clock is ticking towards December 30, 2017. As part of…
https://pioneerinstitute.org/wp-content/uploads/Untitled-design-2-4.png 512 1024 William Smith https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png William Smith2021-05-17 10:18:482021-05-26 10:53:35A Rush to Judgment on Alzheimer’s Drug
The Boston-based Institute for Clinical and Economic Review (ICER) sells itself as an independent source of information on the value of pharmaceuticals. But earlier this month, their bias was again evident when they tried to kneecap a drug for a dreaded disease before there’s even enough data to determine how valuable the drug really is. ICER has adopted this same strategy in the past on innovative drugs for cancer, cystic fibrosis, and other devastating diseases. This time ICER’s target is aducanumab, Biogen’s drug for Alzheimer’s disease.